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U.S. EPA’s (U.S. Environmental Protection 
Agency) ToxRefDB and ToxCast research 
programs, including the review of much of 
the data entered into ToxRefDB. However, 
Janus’s comments do not address the 
ToxRefDB applications presented in our arti-
cle, but instead create hypothetical uses of the 
database and reported data.
For example, in Table 3 of our article 
(Martin et al. 2009a), we presented multi-
gender, multi  site, and multispecies rodent 
tumorigens in order to provide data in a sys-
tematic and computable format for predictive 
toxicity models incorporating potency values. 
In contrast, Janus and CropLife America refer 
to a hypothetical regulatory application of 
this same animal tumorigenicity data in a 
ranking system never suggested in our article. 
The U.S. EPA has gone to great lengths 
to make ToxRefDB and its development as 
transparent as possible. Three manuscripts 
and data sets have been published to date 
(Knudsen et al. 2009; Martin et al. 2009a, 
2009b), and the standardized vocabulary and 
a version of the database are available on the 
ToxRefDB website (U.S. EPA 2008b). We 
will continue to make every effort to publicly 
release information from ToxRefDB as it 
continues to develop.
We recognize the complexity of patho-
logic progression to cancer. The end point 
progression scheme we presented (Martin 
et al. 2009a) included aggregation of 
prolifera  tive, pre  neoplastic, and neo  plastic 
lesions for the development of predictive 
signatures from in vitro data coming from 
the ToxCast research program (U.S. EPA 
2008a). This approach is not controversial in 
the context of predictive toxicology research 
and is supported by the literature (Cohen 
and Arnold 2008; Hanahan and Weinberg 
2000). 
We agree that it is important to incor-
porate pharmacokinetics and metabolism, 
including chemical detoxification and acti-
vation, into predictive toxicology efforts. 
However, this issue is outside the scope of 
our article (Martin et al. 2009a) and is being 
addressed in other aspects of the ToxCast 
research program. 
Two additional papers on multi  genera-
tional reproductive and prenatal develop-
mental toxicity studies in ToxRefDB have 
been recently published (Knudsen et al. 2009; 
Martin et al. 2009b), again with the pri-
mary goal of providing diverse end points for 
predictive modeling as part of the ToxCast 
research program (Dix et al. 2007). Of toxic-
ity end points in ToxRefDB, we are using 
only those of sufficient quality for predictive 
modeling, and we are taking care to distin-
guish between missing versus negative data.
We view ToxRefDB as a valuable 
resource to the scientific community and one 
in which the U.S. EPA, stakeholders, and 
other interested parties can work together 
to ensure the success of ToxRefDB and the 
larger ToxCast effort.
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We were very interested to read the article 
by Schmidt (2009) about the increasing 
number of nano  materials and their potential 
effects. We were especially interested in the 
similarities between carbon nano  tubes and 
chrysotile asbestos fibers. The widespread use 
of asbestos-like substances with similar puta-
tive carcinogenic potential could result in 
the development of other unexpected types 
of cancer.  
The potential carcinogenic risk of nano-
materials that are structurally similar to 
asbestos and have been used in many indus-
trial fields in the last few years has been 
highlighted by Carter (2008). Some studies 
conducted in animal models suggest that 
nano  materials cause free radical–mediated 
cellular DNA damage and consequently have 
an asbestos-like carcinogenic action (Poland 
et al. 2008). 
In addition to meso  thelioma (the typi-
cal cancer index of exposure) or lung can-
cer, asbestos can cause other types of cancer. 
On the basis of our clinical experience, we 
hypothesize that at least a portion of bile 
ducts cancers (i.e., cholangio  carcinomas) are 
caused by exposure to this known carcino-
genic agent.
From 2002 to 2008 we treated 258 patients 
with cholangiocarcinoma at our institute. Over 
the previous year, we carefully interviewed 
66 consecutive patients using a standardized 
questionnaire asking about their exposure to 
asbestos and other known risk factors linked 
to bile duct carcino  genesis (Khan et al. 2008). 
We collected each patient’s remote, recent, 
and occupational clinical history. In addition 
to the association with known risk factors for 
the onset of cholangio  carcinoma, we assessed 
occupational or household exposure to asbes-
tos in 24 patients, 10 of whom did not have 
other certain risk factors (Table 1; Brandi 
et al. 2008). 
Asbestos fibers cause cancer through 
chronic inflammation, amplifying the 
production of oxygen radicals, cytokines, 
growth factors, and pro  inflammatory factors 
responsible for both impaired antioxidant 
and control cell proliferation and apoptosis 
mechanisms in target cells (Manning et al. 
2002). In contrast with findings for pleu-
ral meso  thelioma, the association between 
exposure to asbestos and the development 
of other tumors, such as gastrointestinal and 
Table 1. Characteristics of patients. 
Tumor site
No. of 
patients
Exposure to asbestos
Possible modality 
of exposure
Certain added risk 
factorsa
Household Occupational Ingestion Inhalation Absent Present
ICC   10 7/10 4/10 7/10 4/10 6/10 4/10
Klatskin tumor 6 3/6 3/6 3/6 3/6 3/6 3/6
Ampulla of Vater 1 1/1 – 1/1 – 1/1 –
Main hepatic bile duct 1 – 1/1 – 1/1 – 1/1
GBC 6 6/6 – 6/6 – – 6/6
Abbreviations: GBC, gallbladder carcinoma; HCV, hepatitis C virus; ICC: intrahepatic cholangiocarcinoma. Data updated 
from Brandi et al. (2008). 
aHCV infection or exposure to chemical substances used in industry, sporadic contact with chemical substances used in 
farming, alcohol-related liver cirrhosis or gallstones, or ulcerative colitis and primary sclerosing cholangitis. A 434  v o l u m e  117 | n u m b e r  10 | October 2009  •  Environmental Health Perspectives
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bile duct cancers, has not been univocally 
demonstrated (Gamble 1994). 
The putative increased risk of bile duct 
cancer in subjects exposed to asbestos may 
be due to different mechanisms. The asbestos 
fibers cross the alveolar barrier by inhalation 
or penetrate the gastrointestinal mucosa by 
ingestion. They then reach the inter  stitial 
environ  ment and circulatory system through 
lymphatic vessels and are finally delivered to 
all tissues, namely the liver and bile ducts 
(Miserocchi et al. 2008), where they may 
start a malignant transformation process 
(Wingren 2004). In addition, asbestos fibers 
may reach the bile ducts through the papilla 
of Vater from the intestinal lumen by retro-
grade reflux, as do bacteria, and remain in 
the gallbladder for a long time.
In the near future we may have 
to consider asbestos as another factor 
accounting for the etiopathogenesis of 
cholangio  carcinomas that may explain the 
otherwise mysterious increasing incidence 
of intra  hepatic cholangio  carcinomas in 
Western countries.
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In the letter by O’Brien et al. [Environ Health Perspect 117:A385–386 (2009)], the 
competing financial interest declaration was incorrect. The correct declaration is as follows:
Karen Peabody O’Brien is executive director of Advancing Green Chemistry, a not-for-profit 
organization that receives support from several private foundations (listed online at http://www.
AdvancingGreenChemistry.org/AdvancingGreenChemistry/About_Us.html) to support efforts 
to build the field of green chemistry. J.P. Myers is founder, chief executive officer, and chief sci-
entist for Environmental Health Sciences (EHS), a not-for-profit organization that receives sup-
port from several private foundations (listed online at http://www.environmentalhealthnews.org/
about.html) to support EHS’s mission to advance public understanding of environ  mental health 
sciences. John Warner is president of Warner Babcock Institute for Green Chemistry, a private 
company that applies the principles of green chemis  try in the synthesis of new materials and the 
  redesign of chemical processes.
In the letter by Wilson and Schwarzman [Environ Health Perspect 117:A386 (2009)], 
the last sentence in the first paragraph was incorrect. The corrected sentence is as 
  follows: 
We would add that public policy that accurately reflects current science—and the needs of 
the chemicals market—is instrumental to the widespread adoption of green chemistry.
EHP apologizes for the error.
In the article by La Merrill et al. [Environ Health Perspect 117:1414–1419 (2009)], the keys 
in Figure 3B and Figure 5C should have been in Figure 3C and Figure 5D, respectively. The 
corrected figures are provided below.
EHP apologizes for the errors.
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Figure 3. Diet and maternal TCDD exposure effects on body composition and fasting blood glucose. 
(A) HFD increased postnatal D2 body weights (mean ± SE; n = 27–31 at PNDs 0–26 for HFD, and n = 28 
at PND35 for LFD). (B) HFD (n = 26 mice) increased percent fat at PND35 relative to LFD (mean ± SE; 
n = 28 mice). (C) Fasting blood glucose was increased by HFD and maternal TCDD-treated (n = 5 litters) 
compared with HFD and maternal vehicle-treated (n = 6 litters) female progeny at PND36 (mean ± SE). 
Because diet, but not TCDD, changed body weight and percent body fat, these analyses were done on 
individual D2 mice, with TCDD- and vehicle-treated D2 mice pooled within diet.
*p < 0.05. #p < 0.0001.
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Figure 5. Maternal TCDD exposure and effect of diet on gene expression. Normalized message levels 
are represented as mean ± SE. (C) Induction of Ahr was increased by HFD relative to LFD (n = 11 and 
10 litters, respectively). Measurements were pooled across TCDD and DMBA groups. (D) Induction of 
Cyp1b1 by DMBA was decreased compared with vehicle in HFD-fed but not in LFD-fed D2 mice. LFD 
groups are vehicle (n = 5 litters) and DMBA (n = 5 litters); HFD groups are vehicle (n = 6 litters) and 
DMBA (n = 5 litters). 
*p < 0.05.
Errata